Checkpoint Competitors

CKPT Stock  USD 3.97  0.02  0.50%   
Checkpoint Therapeutics competes with Mustang Bio, Reviva Pharmaceuticals, Fortress Biotech, Kodiak Sciences, and Fortress Biotech; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Checkpoint Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Checkpoint Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Checkpoint Therapeutics Correlation with its peers.
For more information on how to buy Checkpoint Stock please use our How to Invest in Checkpoint Therapeutics guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Checkpoint Therapeutics competition on your existing holdings.
  
At this time, Checkpoint Therapeutics' Return On Capital Employed is comparatively stable compared to the past year. Return On Equity is likely to gain to 3.76 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (10.53). Other Current Assets is likely to gain to about 958.4 K in 2025, whereas Total Assets are likely to drop slightly above 4.6 M in 2025.
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.214.1513.64
Details
Intrinsic
Valuation
LowRealHigh
0.367.2616.75
Details
3 Analysts
Consensus
LowTargetHigh
16.3818.0019.98
Details
Earnings
Estimates (0)
LowProjected EPSHigh
0.000.000.00
Details

Checkpoint Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Checkpoint Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Checkpoint and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Checkpoint Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
ATXIKOD
KODMBIO
CTMXKOD
ATXIMBIO
CTMXMBIO
CTMXATXI
  
High negative correlations   
TILALRN
CTMXALRN
TILPIRS
CTMXPIRS
ALRNPIRS
ALRNATXI

Risk-Adjusted Indicators

There is a big difference between Checkpoint Stock performing well and Checkpoint Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Checkpoint Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
MBIO  6.18 (2.91) 0.00  0.72  0.00 
 15.38 
 53.88 
RVPH  6.00  0.47  0.00 (0.01) 0.00 
 15.38 
 67.62 
FBIOP  2.58 (0.08) 0.00  13.80  0.00 
 7.27 
 15.52 
KOD  5.08 (0.66) 0.00 (0.51) 0.00 
 9.24 
 45.02 
FBIO  2.84 (0.29) 0.00  8.69  0.00 
 9.76 
 22.19 
ATXI  3.90 (1.00) 0.00 (1.13) 0.00 
 6.74 
 31.48 
PIRS  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
ALRN  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
CTMX  3.40 (0.72) 0.00 (0.60) 0.00 
 6.60 
 17.31 
TIL  5.57  0.17  0.00 (0.08) 0.00 
 13.25 
 34.30 

Cross Equities Net Income Analysis

Compare Checkpoint Therapeutics and related stocks such as Mustang Bio, Reviva Pharmaceuticals, and Fortress Biotech Pref Net Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D AShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Cash Conversion CycleOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioFixed Asset Turnover
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Return On AssetsAsset Turnover
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Equity
2010201120122013201420152016201720182019202020212022202320242025
MBIO(5.4 M)(5.4 M)(5.4 M)(5.4 M)(5.4 M)(5.4 M)(12.7 M)(31.3 M)(30.7 M)(48.2 M)(62.1 M)(64.1 M)(78.9 M)(51.6 M)(46.4 M)(48.8 M)
RVPH(846.8 K)(846.8 K)(846.8 K)(846.8 K)(846.8 K)(846.8 K)(846.8 K)(846.8 K)(846.8 K)(846.8 K)(3.8 M)(8.5 M)(24.3 M)(39.3 T)(35.3 T)(33.6 T)
KOD(17.1 M)(17.1 M)(17.1 M)(17.1 M)(17.1 M)(17.1 M)(17.1 M)(27.9 M)(41.4 M)(46.7 M)(133.1 M)(267 M)(333.8 M)(260.5 M)(234.4 M)(222.7 M)
FBIO(10 M)(36.4 M)(27.6 M)(37.2 M)(20.4 M)(48.4 M)(55.1 M)(66.9 M)(84.1 M)(51.8 M)(103 M)(164.8 M)(213.9 M)(60.6 M)(54.6 M)(57.3 M)
ATXI(5.2 M)(5.2 M)(5.2 M)(5.2 M)(5.2 M)(5.2 M)(3.2 M)(12.3 M)(21.3 M)(25.6 M)(5.1 M)(3.7 M)M(10.4 M)(11.9 M)(12.5 M)
CTMX(15.1 M)(15.1 M)(15.1 M)(15.1 M)(30.3 M)(35.4 M)(58.9 M)(43.1 M)(84.6 M)(102.2 M)(32.9 M)(80.6 M)(97.3 M)(569 K)31.9 M33.5 M
TIL(6.5 M)(6.5 M)(6.5 M)(6.5 M)(6.5 M)(6.5 M)(6.5 M)(6.5 M)(6.5 M)(6.5 M)(37.7 M)(156.8 M)(223.2 M)(156.1 M)(74.1 M)(77.8 M)
SPRO(10.2 M)(10.2 M)(10.2 M)(10.2 M)(10.2 M)(10.2 M)(25.5 M)(46.1 M)(41.7 M)(60.2 M)(77.5 M)(91.3 M)(48 M)22.8 M20.5 M21.6 M
ASMB(8.8 M)(34.3 M)(24.8 M)(19.4 M)(23.8 M)(28.5 M)(44.3 M)(42.8 M)(90.8 M)(97.6 M)(59.5 M)(129.9 M)(92.1 M)(61.2 M)(55.1 M)(57.9 M)
ACHL(14 M)(14 M)(14 M)(14 M)(14 M)(14 M)(14 M)(14 M)(14 M)(14 M)(33.2 M)(61.1 M)(71.2 M)(69.7 M)(62.7 M)(65.8 M)
CUE(1.9 M)(1.9 M)(1.9 M)(1.9 M)(1.9 M)(1.9 M)(7.7 M)(23.2 M)(39 M)(36.7 M)(44.8 M)(44.2 M)(52.8 M)(50.7 M)(45.7 M)(47.9 M)

Checkpoint Therapeutics and related stocks such as Mustang Bio, Reviva Pharmaceuticals, and Fortress Biotech Pref Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Checkpoint Therapeutics financial statement analysis. It represents the amount of money remaining after all of Checkpoint Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Checkpoint Therapeutics Competitive Analysis

The better you understand Checkpoint Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Checkpoint Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Checkpoint Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
CKPT MBIO RVPH FBIOP KOD FBIO ATXI CTMX TIL SPRO
 0.50 
 3.97 
Checkpoint
 0.71 
 1.41 
Mustang
 6.73 
 1.11 
Reviva
 2.15 
 6.64 
Fortress
 5.51 
 3.64 
Kodiak
 3.09 
 1.67 
Fortress
 2.60 
 0.79 
Avenue
 10.17 
 0.65 
CytomX
 4.30 
 19.88 
Instil
 4.00 
 0.78 
Spero
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Current Ratio
Net Asset
Profit Margin
EBITDA
Operating Margin
Current Valuation
Price To Book
Retained Earnings
Current Asset
Beta
Number Of Employees
Shares Outstanding
Cash Flow From Operations
Annual Yield
Total Debt
Return On Equity
Z Score
Return On Asset
Number Of Shares Shorted
Book Value Per Share
Current Liabilities
Total Asset
Debt To Equity
Short Ratio
Target Price
Shares Owned By Institutions
Market Capitalization
Price To Earning
Price To Earnings To Growth
Price To Sales
Net Income
Earnings Per Share
Shares Owned By Insiders
Revenue
Working Capital
Cash And Equivalents
Cash Per Share
Gross Profit
Day Typical Price
Accumulation Distribution
Market Facilitation Index
Daily Balance Of Power
Period Momentum Indicator
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Checkpoint Therapeutics Competition Performance Charts

Five steps to successful analysis of Checkpoint Therapeutics Competition

Checkpoint Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Checkpoint Therapeutics in relation to its competition. Checkpoint Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Checkpoint Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Checkpoint Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Checkpoint Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Checkpoint Therapeutics position

In addition to having Checkpoint Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Emerging Markets ETFs Thematic Idea Now

Emerging Markets ETFs
Emerging Markets ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Emerging Markets ETFs theme has 31 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Emerging Markets ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Checkpoint Stock Analysis

When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.